In adults with T2DM receiving pooled incretin drugs including dulaglutide, pharmacist management was linked to greater HbA1c reduction than usual care.
In plain wordsIn adults with diabetes receiving pooled medicines including dulaglutide, pharmacist management was linked to greater blood sugar improvement than usual care.
- Peptide
- Dulaglutide (Trulicity)
- Outcome
- DecreaseHbA1c reduction under pharmacist management
- Study
n = 128
- Comparator
- Usual physician care
- Analysis
- Primary
- Outcome group
- Glycemic control · Metabolic and weight
Measurements
- HbA1c reduction
- 19.9%
- pharmacist-managed group
- HbA1c reduction
- 10.2%
- usual care group
- P value
- 0.03
- between groups
Source sentences
The pharmacist-managed group had a mean 19.9% (SD, 13%) reduction in HbA1c from baseline, compared to a 10.2% (SD, 20.9%) reduction in the usual care group (P = 0.03).
3 context sentences(design, population, supporting numbers)
This was a retrospective study conducted at an outpatient clinic.
Adult patients with T2DM who received an initial prescription for dulaglutide, liraglutide, oral or injectable semaglutide, or tirzepatide during the study period of January 1, 2019, to March 31, 2024, were included.
Patients were stratified into 2 groups based on the care they received: management by a clinical pharmacist (pharmacist-managed care) or by a resident physician (usual care).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).